As of Aug 28
| +0.02 / +1.11%|
The 1 analysts offering 12-month price forecasts for Navidea Biopharmaceuticals Inc have a median target of 2.15, with a high estimate of 2.15 and a low estimate of 2.15. The median estimate represents a +18.13% increase from the last price of 1.82.
The current consensus among 1 polled investment analysts is to Buy stock in Navidea Biopharmaceuticals Inc. This rating has held steady since August, when it was unchanged from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.